文献速递肿瘤 PET/CT核素与放射性配体治疗

高危前列腺癌根治性放疗患者新辅助雄激素剥夺治疗后[68Ga]Ga-PSMA-11-PET/CT代谢反应的意义

The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-05

回顾性分析71例接受根治性放疗的高危前列腺癌患者,评估新辅助雄激素剥夺治疗(nADT)后原发肿瘤SUV早期变化与血清PSA的预后意义。中位随访76.1个月,5年生化无病生存率(bDFS)77.2%、前列腺癌特异性生存率(PCSS)92.2%。多因素分析显示淋巴结转移、Gleason评分>7及nADT后SD/PD是bDFS较差的独立预测因素。

要点

  • nADT后64例(91.1%)原发肿瘤SUV中位下降66.6%(13.2 vs 4.8,p<0.001)。
  • PSA反应与SUV反应高度一致(91.5%),Spearman相关系数0.41(p<0.001)。
  • 淋巴结转移、GS>7及nADT后SD/PD是bDFS较差的独立预测因素。

核心结论

  • nADT后[68Ga]Ga-PSMA-11-PET/CT测得的代谢反应可用于预测接受根治性放疗的高危前列腺癌患者的疾病进展。

研究设计与样本

  • 回顾性分析71例接受根治性放疗的高危前列腺癌患者的临床数据与SUV参数,计算ADT开始前后的血清PSA及原发肿瘤SUV值。
  • 采用单因素和多因素分析探讨预测生化无病生存(bDFS)和前列腺癌特异性生存(PCSS)的预后因素,并用逻辑回归分析识别生化失败(BF)的预测因素。

主要发现

  • 除1例外所有患者血清PSA均反应,下降98.8%(21.8 ng/mL vs 0.3 ng/mL,p<0.001)。
  • 64例(91.1%)患者ADT后原发肿瘤SUV中位下降66.6%(13.2 vs 4.8,p<0.001)。
  • Gleason评分7分患者原发肿瘤SUV反应率显著高于GS>7分患者(59.5% vs 40.5%,p=0.04)。
  • 治疗反应不足患者SUV反应率显著低于完全缓解(CR)或部分缓解(PR)患者(1.1% vs 66.1%,p<0.001)。
  • PSA反应与SUV反应之间呈强且显著相关(Spearman=0.41,p<0.001),一致率高(91.5%)。

关键数值与推荐

  • 中位随访76.1个月,5年bDFS为77.2%,5年PCSS为92.2%。
  • 19例(26.7%)患者在放疗完成后中位44.6个月出现复发。
  • 多因素分析中,淋巴结转移、GS>7及nADT后SD/PD是bDFS较差的独立预测因素;未发现PCSS的显著影响因素。
  • 多因素逻辑回归分析中,高龄、GS>7、淋巴结转移及nADT后SD/PD是BF的独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We examined the prognostic significance of early changes in primary tumor SUV measured with Gallium-68-labeled prostate-specific membrane antigen positron emission tomography ([68Ga]Ga-PSMA-11-PET/CT) and serum PSA values after neoadjuvant androgen deprivation treatment (nADT) in high-risk prostate cancer (PCa) patients treated with definitive radiotherapy (RT). METHODS: The clinical data and SUV parameters of 71 PCa patients were reviewed retrospectively. The serum PSA and primary tumor SUV values were calculated before and after the start of ADT. Using univariable and multivariable analyses, the prognostic factors predicting biochemical disease free survival (bDFS) and prostate cancer specific survival (PCSS) were investigated. In addition, logistic regression analysis was used to identify predictors of biochemical failure (BF). RESULTS: All but one patient responded with a 98.8% reduction in serum PSA (21.8 ng/mL vs. 0.3 ng/mL; p < 0.001), and 64 patients (91.1%) had a median 66.6% decrease in primary tumor SUV after ADT (13.2 vs. 4.8, p < 0.001). The primary tumor SUV response rate was significantly higher in patients with Gleason score (GS) of 7 than in patients with GS > 7 (59.5% vs. 40.5%; p = 0.04), and it was significantly lower in patients with inadequate treatment response than in those with complete (CR) or partial response (PR) (1.1% vs. 66.1%; p < 0.001). There was a strong and significant correlation (Spearman = 0.41, p < 0.001) and a high concordance (91.5%) between PSA response and SUV response after ADT. With a median follow-up time of 76.1 months, the 5-year bDFS and PCSS rates were 77.2% and 92.2%, respectively. Nineteen patients (26.7%) patients had recurrence at a median of 44.6 months after the completion of RT. In multivariate analysis, lymph node metastasis, GS greater than 7, and SD/PD after nADT were independent predictors of worse bDFS. However, no significant factor for PCSS was identified. In the multivariable logistic regression analysis, advanced age, GS of > 7 disease, lymph node metastasis, and SD or PD after nADT were independent predictors of BF. CONCLUSION: These results imply that the metabolic response measured with [68Ga]Ga-PSMA-11-PET/CT after nADT could be used to predict progression in high-risk PCa patients treated with definitive RT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Onal C, Guler OC, Torun N, et al. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37402832. doi:10.1007/s00259-023-06321-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。